GlobeNewswire: Active Biotech Contains the last 10 of 1160 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:49:44ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/06/01/2454164/0/en/Successful-completion-of-the-first-stage-of-the-phase-IIa-clinical-trial-of-naptumomab-in-combination-with-docetaxel-and-the-study-is-now-enrolling-into-the-second-stage.html?f=22&fvtc=4&fvtv=30448Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage2022-06-01T12:00:00Z<![CDATA[Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In the study, the patients are treated with NAP for 4 consecutive days and with docetaxel at a standard dose on day 5 in 21-day treatment cycles. The first stage of this trial required a minimum of two responses out of ten patients to move to the second stage of the trial, which is now enrolling.]]>https://www.globenewswire.com/news-release/2022/06/01/2454164/0/sv/Det-f%C3%B6rsta-steget-av-den-kliniska-fas-IIa-studien-med-naptumomab-i-kombination-med-docetaxel-har-framg%C3%A5ngsrikt-slutf%C3%B6rts-och-rekryteringen-till-andra-steget-av-studien-p%C3%A5g%C3%A5r.html?f=22&fvtc=4&fvtv=30448Det första steget av den kliniska fas IIa studien med naptumomab i kombination med docetaxel har framgångsrikt slutförts och rekryteringen till andra steget av studien pågår2022-06-01T12:00:00Z<![CDATA[Lund, 1 juni 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och dess partner NeoTX tillkännager idag det framgångsrika slutförandet av det första steget av en adaptiv (Simon 2 stage) klinisk fas IIa studie med naptumomab estafenatox (NAP, naptumomab), i kombination med docetaxel i patienter med avancerad icke-småcellig lungcancer (NSCLC) som tidigare har behandlats med kemoterapi och checkpointhämmare (CPI). I studien behandlas patienterna med naptumomab under 4 dagar i följd och med docetaxel i standarddos på dag 5 i 21-dagars behandlingscykler. Det första steget av denna studie krävde minst två responser i tio patienter för att gå vidare till den andra delen av studien, som nu rekryterar.]]>https://www.globenewswire.com/news-release/2022/05/19/2447129/0/en/Annual-General-Meeting-of-Active-Biotech-AB.html?f=22&fvtc=4&fvtv=30448Annual General Meeting of Active Biotech AB2022-05-19T15:00:00Z<![CDATA[The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed.]]>https://www.globenewswire.com/news-release/2022/05/19/2447129/0/sv/%C3%85rsst%C3%A4mma-i-Active-Biotech-AB.html?f=22&fvtc=4&fvtv=30448Årsstämma i Active Biotech AB2022-05-19T15:00:00Z<![CDATA[Active Biotechs årsstämma hölls den 19 maj 2022. Mot bakgrund av coronaviruset genomfördes årsstämman med poströstning, utan fysiskt deltagande. Följande huvudsakliga beslut fattades.]]>https://www.globenewswire.com/news-release/2022/05/18/2446074/0/en/FDA-grants-Orphan-Drug-Designation-for-tasquinimod-in-myelofibrosis.html?f=22&fvtc=4&fvtv=30448FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis2022-05-18T13:00:00Z<![CDATA[Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.]]>https://www.globenewswire.com/news-release/2022/05/18/2446074/0/sv/FDA-beviljar-s%C3%A4rl%C3%A4kemedelsstatus-f%C3%B6r-tasquinimod-vid-behandling-av-myelofibros.html?f=22&fvtc=4&fvtv=30448FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros2022-05-18T13:00:00Z<![CDATA[Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros.]]>https://www.globenewswire.com/news-release/2022/04/28/2430974/0/en/Annual-Report-2021-Active-Biotech-AB-publ.html?f=22&fvtc=4&fvtv=30448Annual Report 2021 Active Biotech AB (publ)2022-04-28T07:40:00Z<![CDATA[Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed.]]>https://www.globenewswire.com/news-release/2022/04/28/2430974/0/sv/%C3%85rsredovisning-2021-Active-Biotech-AB-publ.html?f=22&fvtc=4&fvtv=30448Årsredovisning 2021 Active Biotech AB (publ)2022-04-28T07:40:00Z<![CDATA[Active Biotechs årsredovisning för 2021 finns nu tillgänglig i pdf-format och i ESEF-format (European Single Electronic Format) på www.activebiotech.com. Årsredovisningen kommer enbart att distribueras digitalt. Ladda ner som PDF Lund den 28 april 2022]]>https://www.globenewswire.com/news-release/2022/04/26/2428706/0/en/Active-Biotech-strengthens-the-patent-protection-for-laquinimod-in-eye-disorders.html?f=22&fvtc=4&fvtv=30448Active Biotech strengthens the patent protection for laquinimod in eye disorders2022-04-26T06:30:00Z<![CDATA[Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be granted on May 11, 2022, under patent number EP 3886858, and provides protection and market exclusivity of laquinimod in this field of use until 2040. A similar application is pending in the US Patent Office.]]>https://www.globenewswire.com/news-release/2022/04/26/2428706/0/sv/Active-Biotech-st%C3%A4rker-patentskyddet-f%C3%B6r-laquinimod-vid-%C3%B6gonsjukdomar.html?f=22&fvtc=4&fvtv=30448Active Biotech stärker patentskyddet för laquinimod vid ögonsjukdomar2022-04-26T06:30:00Z<![CDATA[Lund, 26 april 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelade idag att Europeiska patentverket (EPO) har utfärdat ett beslut om att bevilja Active Biotechs patent relaterat till användning av laquinimod som behandling av ögonsjukdomar associerat med onormal kärltillväxt. Patentet kommer att beviljas den 11 maj 2022, under patentnummer EP 3886858, och ger skydd och marknadsexklusivitet för laquinimod inom detta medicinska användningsområde fram till 2040. En liknande ansökan pågår hos det amerikanska patentverket.]]>